Clovis Oncology Inc. (NASDAQ:CLVS) shot up 6.9% during trading on Monday . The company traded as high as $18.45 and last traded at $18.44, with a volume of 1,166,468 shares changing hands. The stock had previously closed at $17.25.

A number of brokerages have recently commented on CLVS. Credit Suisse Group AG lifted their price objective on Clovis Oncology to $19.00 in a research report on Wednesday. Mizuho lifted their price objective on Clovis Oncology from $15.00 to $23.00 and gave the company a “neutral” rating in a research report on Wednesday. Piper Jaffray Cos. set a $14.00 price objective on Clovis Oncology and gave the company a “hold” rating in a research report on Thursday, August 18th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Clovis Oncology in a research report on Thursday, August 18th. Finally, Zacks Investment Research raised Clovis Oncology from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a research report on Thursday, August 11th. Six analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $30.06.

The company has a 50-day moving average price of $15.55 and a 200 day moving average price of $16.12. The company’s market cap is $930.18 million.

Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($2.07) EPS for the quarter, topping analysts’ consensus estimates of ($2.13) by $0.06. During the same quarter in the prior year, the firm posted ($2.10) EPS. On average, equities analysts expect that Clovis Oncology Inc. will post ($9.33) EPS for the current year.

A hedge fund recently bought a new stake in Clovis Oncology stock. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Clovis Oncology Inc. (NASDAQ:CLVS) during the fourth quarter, according to its most recent filing with the SEC. The institutional investor purchased 33,500 shares of the biopharmaceutical company’s stock, valued at approximately $1,172,000. Connor Clark & Lunn Investment Management Ltd. owned 0.09% of Clovis Oncology as of its most recent filing with the SEC.

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.